Explore

Trendline Trendline
Bristol Myers Squibb to Present New Oncology Data at ASCO 2026 Highlighting Innovative Cancer Treatments

Bristol Myers Squibb to Present New Oncology Data at ASCO 2026 Highlighting Innovative Cancer Treatments

Bristol Myers Squibb to Present New Oncology Data at ASCO 2026 Highlighting Innovative Cancer Treatments
Trendline Trendline
SystImmune to Present New Clinical Data on Izalontamab Brengitecan at ASCO 2026

SystImmune to Present New Clinical Data on Izalontamab Brengitecan at ASCO 2026

SystImmune to Present New Clinical Data on Izalontamab Brengitecan at ASCO 2026
Trendline Trendline
Formosa Pharmaceuticals to Present TSY-310 at ASCO 2026, Highlighting Antitumor Efficacy

Formosa Pharmaceuticals to Present TSY-310 at ASCO 2026, Highlighting Antitumor Efficacy

Formosa Pharmaceuticals to Present TSY-310 at ASCO 2026, Highlighting Antitumor Efficacy
Trendline Trendline
Accent Therapeutics to Present Clinical Study on ATX-295 at ASCO Meeting, Targeting Chromosomal Instability in Cancer

Accent Therapeutics to Present Clinical Study on ATX-295 at ASCO Meeting, Targeting Chromosomal Instability in Cancer

Accent Therapeutics to Present Clinical Study on ATX-295 at ASCO Meeting, Targeting Chromosomal Instability in Cancer
Trendline Trendline
Formosa Pharmaceuticals to Present TSY-310 at ASCO Annual Meeting, Highlighting Antitumor Efficacy

Formosa Pharmaceuticals to Present TSY-310 at ASCO Annual Meeting, Highlighting Antitumor Efficacy

Formosa Pharmaceuticals to Present TSY-310 at ASCO Annual Meeting, Highlighting Antitumor Efficacy
Trendline Trendline
858 Therapeutics Reports Promising Results from Phase 1/2 Trial of PARG Inhibitor ETX-19477 in Cancer Treatment

858 Therapeutics Reports Promising Results from Phase 1/2 Trial of PARG Inhibitor ETX-19477 in Cancer Treatment

858 Therapeutics Reports Promising Results from Phase 1/2 Trial of PARG Inhibitor ETX-19477 in Cancer Treatment
Trendline Trendline
Eisai Presents New Clinical Evidence for Lenvatinib at ASCO 2026

Eisai Presents New Clinical Evidence for Lenvatinib at ASCO 2026

Eisai Presents New Clinical Evidence for Lenvatinib at ASCO 2026
Trendline Trendline
Gilead and Kite Showcase Advances in Oncology with New Data on Antibody-Drug Conjugates and Cell Therapy

Gilead and Kite Showcase Advances in Oncology with New Data on Antibody-Drug Conjugates and Cell Therapy

Gilead and Kite Showcase Advances in Oncology with New Data on Antibody-Drug Conjugates and Cell Therapy
Trendline Trendline
Aulos Bioscience's Imneskibart Shows Promise in Refractory Metastatic Melanoma

Aulos Bioscience's Imneskibart Shows Promise in Refractory Metastatic Melanoma

Aulos Bioscience's Imneskibart Shows Promise in Refractory Metastatic Melanoma
Trendline Trendline
Corbus Pharmaceuticals Appoints Nishant Saxena as Chief Business Officer Amidst Key Clinical Developments

Corbus Pharmaceuticals Appoints Nishant Saxena as Chief Business Officer Amidst Key Clinical Developments

Corbus Pharmaceuticals Appoints Nishant Saxena as Chief Business Officer Amidst Key Clinical Developments
Trendline Trendline
Lantern Pharma's LP-300 Trial for Never-Smokers with NSCLC Advances with FDA Support

Lantern Pharma's LP-300 Trial for Never-Smokers with NSCLC Advances with FDA Support

Lantern Pharma's LP-300 Trial for Never-Smokers with NSCLC Advances with FDA Support
Trendline Trendline
Lantern Pharma's HARMONIC Trial Receives FDA Support for Protocol Amendments in NSCLC Treatment

Lantern Pharma's HARMONIC Trial Receives FDA Support for Protocol Amendments in NSCLC Treatment

Lantern Pharma's HARMONIC Trial Receives FDA Support for Protocol Amendments in NSCLC Treatment